OM:SOBIBiotechs
How Investors May Respond To Swedish Orphan Biovitrum (OM:SOBI) Aspaveli’s Positive EU Kidney-Disease Opinion
Swedish Orphan Biovitrum AB (Sobi) recently received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use recommending marketing authorisation of Aspaveli (pegcetacoplan) to treat adults and adolescents with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis across the European Union.
If approved by the European Commission, Aspaveli would become the first authorised therapy for these rare, severe kidney diseases in patients 12...